Abstract

β-lactamases (BLs) represent the most frequent cause of antimicrobial resistance in Gram-negative bacteria. Despite the continuous efforts in the development of BL inhibitors (BLIs), new BLs able to hydrolyze the last developed antibiotics rapidly emerge. Moreover, the insurgence rate of effective mutations is far higher than the release of BLIs able to counteract them. This results in a shortage of antibiotics that is menacing the effective treating of infectious diseases. The situation is made even worse by the co-expression in bacteria of BLs with different mechanisms and hydrolysis spectra, and by the lack of inhibitors able to hit them all. Differently from other targets, BL flexibility has not been deeply exploited for drug design, possibly because of the small protein size, for their apparent rigidity and their high fold conservation. In this mini-review, we discuss the evidence for BL binding site dynamics being crucial for catalytic efficiency, mutation effect, and for the design of new inhibitors. Then, we report on identified allosteric sites in BLs and on possible allosteric inhibitors, as a strategy to overcome the frequent occurrence of mutations in BLs and the difficulty of competing efficaciously with substrates. Nevertheless, allosteric inhibitors could work synergistically with traditional inhibitors, increasing the chances of restoring bacterial susceptibility towards available antibiotics.

Highlights

  • Antimicrobial resistance (AMR) is critically threatening the treatment of a large range of infections caused by bacteria able to inactivate even last resort antibiotics [1]

  • (NMC-A), the Serratia fonticola resistant to carbapenem BL (SFC-1) and Serratia marcescens enzyme (SME), the plasmid-encoded Klebsiella pneumoniae carbapenemase (KPC) and Guiana Extended Spectrum (GES)-type enzymes; for class C, only the plasmid-mediated AmpC β-lactamase active on cephamycins (CMY-10), for class D, the acquired OXAcillinase carbapenemase (OXA)-type enzymes

  • The flexibility of New Delhi Metallo-beta-lactamase 1 (NDM-1), which is necessary to perform the hydrolytic reaction and incremented by the high mutation rate, is responsible for the development of resistant bacteria [54]

Read more

Summary

Introduction

Antimicrobial resistance (AMR) is critically threatening the treatment of a large range of infections caused by bacteria able to inactivate even last resort antibiotics [1]. Resistance is often caused by the overexpression of BLs (β-lactamases) able to hydrolyze and inactivate a vast number of β-lactam antibiotics [7,8]. As a matter of fact, carbapenemases are currently among the most relevant/studied targets for the development of new antibacterials They include, for class A, the chromosomally-encoded and clavulanic acid-inhibited. Imipenem-hydrolyzing beta-lactamase (IMI), the Not metalloenzyme carbapenemase of class A (NMC-A), the Serratia fonticola resistant to carbapenem BL (SFC-1) and Serratia marcescens enzyme (SME), the plasmid-encoded Klebsiella pneumoniae carbapenemase (KPC) and Guiana Extended Spectrum (GES)-type enzymes; for class C, only the plasmid-mediated AmpC β-lactamase active on cephamycins (CMY-10), for class D, the acquired OXAcillinase carbapenemase (OXA)-type enzymes. The identification of allosteric sites communicating with the orthosteric one would allow the design of allosteric inhibitors less susceptible to intrinsic and acquired resistance

BL Binding Site Flexibility
Class A Flexibility
Flipped-in
A BLs observed allow
Class D Flexibility
Allosteric Regulation in BLs
Allosteric
16 Å away
Allosteric effectors in site
Identification of Cryptic Allosteric Sites in Class A BLs
Relevant Residues Mediating Allosteric Regulation in Class A BLs
A BLs hasSHV-1 been thoroughly in the last decade helping
Allosteric Effectors and Mechanisms in Class B BLs
Allosteric Effectors and Mechanisms in Class C BLs
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call